Pulse Biosciences Highlights nPulse™ Technology Presentation at Heart Rhythm Society 2026 Annual Meeting
Pulse Biosciences has announced a strong presence at the upcoming Heart Rhythm Society Annual Meeting, where it will showcase its proprietary nPulse™ platform and present new clinical and preclinical data supporting its innovative nanosecond pulsed field ablation (nsPFA™) technology. The event, scheduled to take place from April 23 to 26 in Chicago, is one of the most prominent global forums for advancements in cardiac electrophysiology and arrhythmia treatment.
At the center of Pulse Biosciences’ participation is its nPulse™ Cardiac Catheter, a device designed to deliver nsPFA™ energy for the treatment of cardiac arrhythmias, particularly atrial fibrillation. Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder worldwide and is associated with significant morbidity, including increased risk of stroke, heart failure, and reduced quality of life. As such, there is ongoing demand for safer, more effective, and more precise ablation technologies.
Pulse Biosciences’ nsPFA™ technology represents a next-generation approach to cardiac ablation. Unlike traditional thermal ablation methods—such as radiofrequency or cryoablation—which rely on heat or freezing to destroy tissue, nsPFA™ uses ultra-short electrical pulses delivered in nanoseconds. These pulses create controlled disruptions in cell membranes, leading to targeted cell death while minimizing damage to surrounding structures such as blood vessels, nerves, and the esophagus. This non-thermal mechanism has the potential to improve both the safety and precision of ablation procedures.
At HRS 2026, the company will present late-breaking clinical data highlighting one-year outcomes from a European feasibility study evaluating nsPFA™ delivered via a compliant cardiac catheter. These results are expected to provide important insights into the durability and long-term effectiveness of this approach in treating atrial fibrillation. The data will be presented during a high-profile late-breaking clinical science session, underscoring the growing interest in pulsed field ablation (PFA) technologies within the electrophysiology community.
The presentation, titled “One-year Outcomes of Nanosecond Pulsed Field Ablation Using a Compliant Catheter to Treat Atrial Fibrillation: A Multicenter Experience,” will be delivered by Vivek Reddy of the Icahn School of Medicine at Mount Sinai. The study reflects a multicenter effort, indicating that the technology has been evaluated across diverse clinical settings, which is critical for assessing real-world applicability. Longer-term outcome data are particularly valuable in the context of AF ablation, where recurrence rates and durability of lesions remain key considerations.
In addition to formal presentations, Pulse Biosciences will participate in a live procedural demonstration as part of the PFA Live Case Summit, a major highlight of the conference. This session will feature real-time transmission of a clinical case performed at Motol and Homolka University Hospital in Prague. The procedure will be conducted by experienced electrophysiologists John Peter and Moritoshi Funasako.
The live case, titled “Pulmonary Vein Isolation (PVI) plus Posterior Wall Ablation (PWA) Using Nanosecond PFA,” will demonstrate the use of nsPFA™ technology in a real-world clinical environment. Pulmonary vein isolation is a cornerstone of AF ablation procedures, aimed at preventing abnormal electrical signals originating in the pulmonary veins from triggering arrhythmias. The addition of posterior wall ablation may further enhance procedural efficacy in certain patient populations. By showcasing this combined approach using nsPFA™, the demonstration will provide valuable insights into procedural workflow, lesion formation, and real-time device performance.
Beyond the live case and late-breaking session, Pulse Biosciences will also contribute to the scientific program through oral presentations and poster sessions. One oral abstract, presented by Petr Neuzil, will focus on the use of a compliant circular catheter for delivering nsPFA™ in atrial fibrillation patients. This study, also based on a multicenter experience, will further expand on the clinical evidence supporting the technology’s effectiveness and adaptability in different procedural settings.
Complementing the clinical data, preclinical research will also be highlighted during the meeting. A featured poster presented by Masaya Shinohara from the Icahn School of Medicine at Mount Sinai will examine how factors such as energy dose and catheter orientation influence lesion formation in focal nsPFA™ applications. Understanding these parameters is essential for optimizing treatment protocols and ensuring consistent outcomes across patients. Such preclinical insights play a crucial role in refining device design and procedural techniques before broader clinical adoption.
The company’s presence at HRS 2026 extends beyond individual sessions, with its technology suite and nPulse™ platform featured at its exhibit booth. Attendees will have the opportunity to explore the underlying science and engineering behind nsPFA™, as well as its potential applications beyond atrial fibrillation. As pulsed field ablation continues to gain traction as a promising alternative to traditional ablation methods, companies like Pulse Biosciences are working to differentiate their technologies through innovations in energy delivery, catheter design, and clinical performance.
The growing interest in PFA technologies reflects a broader shift in the field of cardiac electrophysiology toward safer and more tissue-selective ablation strategies. Early clinical data from various PFA platforms have suggested reduced risk of complications such as esophageal injury and pulmonary vein stenosis—issues that have historically been associated with thermal ablation techniques. Pulse Biosciences’ nsPFA™ approach aims to build on these advantages while offering unique capabilities enabled by nanosecond pulse durations.
As the electrophysiology community continues to evaluate the relative merits of different PFA systems, robust clinical evidence and real-world experience will be critical in determining which technologies ultimately achieve widespread adoption. The data being presented at HRS 2026, including one-year outcomes and multicenter experiences, represent an important step in this process.
In summary, Pulse Biosciences’ participation in HRS 2026 highlights its commitment to advancing next-generation ablation technologies for the treatment of atrial fibrillation. Through a combination of clinical data presentations, live procedural demonstrations, and scientific discussions, the company aims to showcase the potential of nsPFA™ to improve patient outcomes and redefine standards of care in cardiac electrophysiology.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.
Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
Source Link:https://www.businesswire.com/
